The FDA is now cautioning about the use of albumin or plasma protein fraction (PPF) in seriously ill patients
October 1998
The FDA is now cautioning about the use of albumin or plasma protein fraction (PPF) in seriously ill patients.
A new meta-analysis in the British Medical Journal suggests a 6% HIGHER mortality when albumin is given to seriously ill patients with hypovolemia...burns...or hypoproteinemia. This would mean one excess death per 17 treated patients.
Researchers suspect this may be partly due to the leakage of albumin and water from capillaries...leading to pulmonary edema, poor tissue oxygenation, and multiorgan failure.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote